Eupraxia Pharmaceuticals (TSE:EPRX) has released an update.
Eupraxia Pharmaceuticals Inc. has bolstered its leadership team with the appointment of Dr. Amanda Malone as Chief Operating and Scientific Officer and Dr. Rahul Sarugaser as Executive Vice President of Corporate Development. With a focus on advancing its proprietary DiffuSphere™ technology for improved drug delivery, Eupraxia is poised for growth in various clinical settings, leveraging Dr. Malone’s research and development expertise and Dr. Sarugaser’s capital markets experience. The company, known for its innovative extended-release products targeting unmet medical needs, recently achieved a milestone with a successful phase 2 study in osteoarthritis.
For further insights into TSE:EPRX stock, check out TipRanks’ Stock Analysis page.
